|Chemical and physical data|
|Molar mass||1148.403 g/mol|
|3D model (JSmol)|
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.
- Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy. 8 (3): 351–9. doi:10.1517/146565188.8.131.521. PMID 17266469.
- Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|